Effects of Ultrasound-guide Hypertonic Dextrose Injection for Chronic Subacromial Bursitis

NCT ID: NCT04916353

Last Updated: 2021-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-10

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the echoguide hypertonic injection and compared steroid injection in subacromial bursitis patients about clinical and ultrasound image presentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subacromial bursitis is one of the major causes of chronic refractory shoulder pain. It can cause patients with shoulder pain when shoulder exercise and heavy lifting and limiting the range of motion. It can also influence the sleep quality due to pain symptoms of the shoulder. Usually, these patients had limited response to medication and physical modality. Steroid injection was often adopted for intervention, but the adverse effects should be considered. Therefore, prolotherapy was taken as an alternative treatment for chronic subacromial bursitis. It involves the injection of small volumes of an irritant agent, most commonly a hyperosmolar dextrose solution, at the lesion site. Hyperosmolar dextrose appears to be the most commonly used agent today. The aim of this study is to investigate hypertonic injections in subacromial bursitis patients about clinical and ultrasound image presentation. The investigators conducted a double-blinded randomized controlled trial for 60 participants with chronic shoulder pain for 3 months with subacromial bursitis. In the study group, the echo guide 20% dextrose water was injected into the lesion site, and the control group received the echo guide steroid injection. ROM, SPADI, VAS, x-ray, and ultrasound data were obtained at baseline. At weeks 2, 6, 12, ROM, SPADI, VAS, and ultrasound data were evaluated. The ANOVA and independent t-test are applied for analysis by SPSS 20.0 with a P value less than 0.05 as statistical significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Shoulder Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

20% hypertonic dextrose water injection group

echo guide 20% dextrose water 3ml was injection in lesion site

Group Type EXPERIMENTAL

hypertonic dextrose water

Intervention Type DRUG

20% hypertonic dextrose water injection for chronic shoulder pain

Steroid injection group

Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group

Group Type ACTIVE_COMPARATOR

Triamcinolone Acetonide.

Intervention Type DRUG

Triamcinolone Acetonide 40mg/1ml injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hypertonic dextrose water

20% hypertonic dextrose water injection for chronic shoulder pain

Intervention Type DRUG

Triamcinolone Acetonide.

Triamcinolone Acetonide 40mg/1ml injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prolotherapy group comparatice group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged more than 20 years old with diagnosis of chronic supraspinatus tendinosis by ultrasound and clinical shoulder pain lasting for more than 3 months.

Exclusion Criteria

* History of shoulder fracture and operation, with frozen shoulder or full thickness ruptur of rotator cuff, steroid, or hyaluronic acid, or platelet rich plasma (PRP) injection during the period of intervention and following up.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Taipei Medical University Shuang Ho Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ShihWei Huang

Attending Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lien-Chieh Lin

Role: STUDY_CHAIR

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shuang Ho Hospital

New Taipei City, Zhonghe Dist, Taiwan

Site Status NOT_YET_RECRUITING

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

New Taipei City, Zhonghe Dist, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ShihWei Huang

Role: CONTACT

+88622490088 ext. 1601

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ShihWei Huang

Role: primary

+88622490088 ext. 1601

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N201812061

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.